EA200970332A1 - Новые антигены и антитела, ассоциированные с аденокарциномой панкреатического протока - Google Patents

Новые антигены и антитела, ассоциированные с аденокарциномой панкреатического протока

Info

Publication number
EA200970332A1
EA200970332A1 EA200970332A EA200970332A EA200970332A1 EA 200970332 A1 EA200970332 A1 EA 200970332A1 EA 200970332 A EA200970332 A EA 200970332A EA 200970332 A EA200970332 A EA 200970332A EA 200970332 A1 EA200970332 A1 EA 200970332A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
pda
pancreatic
adhenocarcinoma
new
Prior art date
Application number
EA200970332A
Other languages
English (en)
Other versions
EA016731B1 (ru
Inventor
Франческо Новелли
Барбара Томаино
Паола Каппелло
Original Assignee
Рибовакс Байотекнолоджиз Са
Биолине Дианьостичи Срл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рибовакс Байотекнолоджиз Са, Биолине Дианьостичи Срл filed Critical Рибовакс Байотекнолоджиз Са
Publication of EA200970332A1 publication Critical patent/EA200970332A1/ru
Publication of EA016731B1 publication Critical patent/EA016731B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к новым белковым антигенам человека и соответствующим антителам, которые были идентифицированы как специфически экспрессируемые в ассоциации с аденокарциномой панкреатического протока человека (PDA). В частности, идентифицированы новые фосфорилированные изоформы альфа-енолазы в трансформированных клеточных линиях панкреатического происхождения и антитела, связывающие такие изоформы, которые присутствуют специфически в сыворотках пациентов с PDA. Указанные белки и антитела могут использоваться для диагностики и лечения PDA и других видов рака, которые характеризуются соответствующими, близкими к рассматриваемым молекулярными особенностями.
EA200970332A 2006-09-29 2007-09-28 Изоформа человеческой альфа-енолазы, антитело к указанной изоформе и способы их применения EA016731B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06121552 2006-09-29
EP06126726 2006-12-20
PCT/EP2007/060305 WO2008037792A1 (en) 2006-09-29 2007-09-28 Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma

Publications (2)

Publication Number Publication Date
EA200970332A1 true EA200970332A1 (ru) 2009-10-30
EA016731B1 EA016731B1 (ru) 2012-07-30

Family

ID=38895810

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970332A EA016731B1 (ru) 2006-09-29 2007-09-28 Изоформа человеческой альфа-енолазы, антитело к указанной изоформе и способы их применения

Country Status (18)

Country Link
US (1) US8071721B2 (ru)
EP (1) EP2069395B1 (ru)
JP (1) JP2010505104A (ru)
KR (1) KR20090094227A (ru)
CN (1) CN101578295B (ru)
AT (1) ATE542831T1 (ru)
AU (1) AU2007301966B2 (ru)
BR (1) BRPI0717282A2 (ru)
CA (1) CA2664841A1 (ru)
DK (1) DK2069395T3 (ru)
EA (1) EA016731B1 (ru)
ES (1) ES2381304T3 (ru)
IL (2) IL197868A (ru)
NO (1) NO20091662L (ru)
NZ (1) NZ576409A (ru)
PL (1) PL2069395T3 (ru)
PT (1) PT2069395E (ru)
WO (1) WO2008037792A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2725548A1 (en) * 2008-05-09 2009-11-12 Duke University Autoantibodies in the detection and treatment of cancer
IT1398782B1 (it) * 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
ITTO20120523A1 (it) * 2012-06-15 2013-12-16 Natimab Therapeutics S R L Procedimento e kit per la diagnosi in vitro dell'adenocarcinoma duttale pancreatico o per determinare la predisposizione all'adenocarcinoma duttale pancreatico
EP3083697B1 (en) * 2013-12-20 2019-04-17 Development Center for Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
AU2015204452A1 (en) 2014-01-13 2016-08-11 Berg Llc Enolase 1 (Eno1) compositions and uses thereof
CN115786317B (zh) * 2022-12-12 2026-03-20 江苏三联生物工程股份有限公司 重组神经元特异性烯醇化酶及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753446A (en) * 1993-04-15 1998-05-19 National Jewish Center For Immunology & Respiratory Medicine Mitogen ERK kinase kinase (MEKK) assay

Also Published As

Publication number Publication date
NO20091662L (no) 2009-06-29
KR20090094227A (ko) 2009-09-04
EP2069395B1 (en) 2012-01-25
PT2069395E (pt) 2012-04-27
US8071721B2 (en) 2011-12-06
ES2381304T3 (es) 2012-05-25
CA2664841A1 (en) 2008-04-03
PL2069395T3 (pl) 2012-06-29
NZ576409A (en) 2012-02-24
US20100028907A1 (en) 2010-02-04
JP2010505104A (ja) 2010-02-18
ATE542831T1 (de) 2012-02-15
BRPI0717282A2 (pt) 2013-10-15
IL197868A (en) 2013-03-24
IL197868A0 (en) 2011-08-01
CN101578295B (zh) 2013-02-27
EP2069395A1 (en) 2009-06-17
DK2069395T3 (da) 2012-05-14
WO2008037792A1 (en) 2008-04-03
IL218442A0 (en) 2012-04-30
CN101578295A (zh) 2009-11-11
AU2007301966B2 (en) 2013-02-21
AU2007301966A1 (en) 2008-04-03
EA016731B1 (ru) 2012-07-30

Similar Documents

Publication Publication Date Title
CY1121023T1 (el) Συζευγματα αντισωματος φαρμακου (adc) τα οποια δεσμευονται σε 191p4d12 πρωτεϊνες
MY162056A (en) Diagnosis and treatment of cancer using anti -ereg antibody
MY150400A (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
ECSP12012272A (es) Proteínas que se unen al tnf-?
CY1117236T1 (el) Μονοκλωνικα αντισωματα εναντι γλυπικανης-3
MX2010002269A (es) Composiciones y metodos que comprenden proteinas de union para adalimumab.
CY1119539T1 (el) Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
EA201492253A1 (ru) Конструкторы, связывающиеся с ron, и способы их использования
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
EP1996716A4 (en) MANIPULATED ANTI-PROSTATE STEAM CELL RESPONSIVES (PSCA) ANTIBODIES FOR CANCER TARGETING
BRPI0808940A8 (pt) anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor
PH12013500347A1 (en) Antibodies to matrix metalloproteinase 9
MX2008009886A (es) Anticuerpos que enlazan par-2.
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
EA201001212A8 (ru) Лечение микробных инфекций
EA200970332A1 (ru) Новые антигены и антитела, ассоциированные с аденокарциномой панкреатического протока
UA105760C2 (ru) Антитело против bst2
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
WO2008109533A3 (en) Human antibodies that bind multiple irta family proteins, and uses thereof
WO2022081443A3 (en) Anti-psma antibodies and uses thereof

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU